4-Methylumbelliferone (4-MU)

Name: 4-Methylumbelliferone (4-MU)
Brand: Selleck Chemicals
SKU: S2256
Rating: 5 (2 reviews)

For research use only.

Catalog No.S2256

2 publications

4-Methylumbelliferone (4-MU) Chemical Structure

CAS No. 90-33-5

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Selleck's 4-Methylumbelliferone (4-MU) has been cited by 2 publications

Mol Carcinog, 2019, 58(3):321-333

PubMed: 30365189 ( click the link to review the publication )

J Med Virol, 2019, 91(8):1440-1447

PubMed: 30900754 ( click the link to review the publication )

Purity & Quality Control

Biological Activity

Description

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
COS1 cells	MXLGeY5kfGmxbjDhd5NigQ>?			NXfK[3JVSWexbnnzeIlkKGGldHn2bZR6KHejczDk[ZRmem2rbnXkJIlvKEORU{GgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCJQVygOE1RWEGUIHfhcY1iKHKnY3XweI9zNCCHQ{WwQVAvODJzIN88US=>	M2rYZlEzPjF5OUK0
CV-1 cells	Mn3YSpVv[3Srb36gZZN{[Xl?			NFXsWI1O[XirbXHsJJJmeG:{dHXyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUHXyc5hqe2:vZTDwdo9tcW[ncnH0c5Ih[WO2aY\heIVlKHKnY3XweI9zKGejbX3hJGdidDRiY3jpcYVzcWNiaX6geJJidnOrZX70cJkhfHKjboPm[YN1\WRiQ2[tNUBk\WyuczDifUBnfW6ldHnvcoFtKGG\|c3H5MEBGSzVyPUCuNFQ{KM7:TR?=	MY[xNVczODh3NB?=
COS-1 cells	MXLGeY5kfGmxbjDhd5NigQ>?			MlzHTY4hfmm2cn:geJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIIDldo95cXOxbXWgdJJwdGmoZYLheI9zKGGldHn2ZZRm\CC{ZXPldJRweiCpYX3tZUBu\WG\|dYLl[EBqdiCSUFHSMWdCVDRiY3jpcYVzcWNiQ1;TMVEh[2WubIOsJGVEPTB;MD6wNkDPxE1?	NW[5b2w5OTJ6N{O1NVc>
CV-1 cells	MWjGeY5kfGmxbjDhd5NigQ>?			MVjBZ5RqfmG2aX;uJI9nKHCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTDt[YF{fXKnZDDifUBqdmS3Y4Tpc44hd2ZiNUClJI9nKG2jeHnteY0h[WytYXzpcoUheGixc4DoZZRie2ViYXP0bZZqfHluIITyZY5{\mWldHnvckBie3OjeTDpckBEXi1zIHPlcIx{NCCHQ{WwQVAvODh7MUOg{txO	MXS5PFM3PjJy
CV-1 cells	NE\p[4hHfW6ldHnvckBie3OjeR?=			M13hemlvKH[rdILvJJRz[W6\|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJI9nKFCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTCoVHBCWiliZYjwdoV{e2WmIHnuJGNXNTFiY3XscJMtKEWFNUC9NE4xPiEQvF2=	NULpWVlNQDV5NkmwOy=>
COS-1 cells	NWGxWHRITnWwY4Tpc44h[XO\|YYm=			NIrQOYZKdiC4aYTyc{Bi\2:waYP0JIFkfGm4aYT5JJRme3SnZDDmc5IhfHKjboPhZ5RqfmG2aX;uJIlvKGi3bXHuJHBRSVJiZ3HtcYEuT2GuNDDjbIlu\XKrYzDDU3MuOSClZXzsd{whTUN3ME2wMlAzKM7:TR?=	MoDWNVI4Ojl4Nki=
CV-1 cells	MnO1SpVv[3Srb36gZZN{[Xl?			NH7FeGFKdiC4aYTyc{BmfmGudXH0bY9vKGGpYXnud5QhWliULXHsdIhiN1CSQWKt[4FudWFiaX6gR3YuOSClZXzsd{BjgSClb4TyZY5{\mWldHnvckBie3OjeTD3ZZMh\GW2ZYLtbY5m\CxiRVO1NF0xNjN{NTFOwG0>	MoD4NVI6PTRyNkG=
HepG2 cells	M3;OfGZ2dmO2aX;uJIF{e2G7			M{fQbGVn\mWldHn2[UBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{whTUN3ME2wMlA{QSEQvF2=	NFzCcIIyPjFyN{G1NC=>
Huh7 cells	MmLISpVv[3Srb36gZZN{[Xl?			NG\3N2hHfW6ldHnvcoFtKGGldHn2bZR6KGG2IHj1cYFvKFCSQWKg[4FudWFiaX6gTJVpPyClZXzsd{BjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6yNkDPxE1?	MmLlNVY{PjZ4MEG=
Huh7 cells	NF3DfGdHfW6ldHnvckBie3OjeR?=			MUjF[oZm[3Rib36gVHBCWiCpYX3tZUB1emGwc3HjeIl3[XSrb36gZYN1cX[rdImgbY4hUHWqNzDj[YxteyxiRVO1NF0xNjJ{IN88US=>	Mn3ENVY1PTFyOEe=
U2OS cells	NUn6dZdMTnWwY4Tpc44h[XO\|YYm=			NF7WNZdG\m[nY4Sgc44hWFCDUnfhcY1iKHS{YX7zZYN1cX[jdHnvckBi[3Srdnn0fUBqdiCXMl;TJINmdGy\|LDDFR\|UxRTBwMEOg{txO	M4f3U\|E3OzByOUS0
CV1 cells	MWDGeY5kfGmxbjDhd5NigQ>?			MVvUdoFve2GldHn2ZZRqd25ib3[gVHBCWmejbX3hJIlvKEOYMTDj[YxteyxiRVO1NF0xNjB5NjFOwG0>	NHrkXJUyPjh{MUe2PS=>
human keratinocytes	M{nrO3Bzd2yrZnXyZZRqd25iYYPzZZk>			MlXDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCtZYLheIlvd2O7dHXzMEBGSzVyPUig{txO	NYi2VW85OTZ6MkG3Olk>
HT29 cell	MVHQdo9tcW[ncnH0bY9vKGG\|c3H5			NWPXbIxYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHygcIlv\SxiRVO1NF01PSEQvF2=	MoOxNVY5OjF5Nkm=
NIH3T3 cells	MWLGeY5kfGmxbjDhd5NigQ>?			NFq4eIdC[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKHS{YX7z[oVkfGWmIHnuJG5KUDOWMzDj[YxteyCkeTDseYNq\mW{YYPlJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwM{Kg{txO	M{DRbVE3QDV2MEi1
CV1 cells	MlrJSpVv[3Srb36gZZN{[Xl?			M1\LbXRz[W6\|YXP0bZZifGmxbjDv[kBpfW2jbjDQVGFT\2GvbXGgbY4hS1ZzIHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlMxQCEQvF2=	M1nGSVE3QTdyM{mx
Huh7 cells	MX;GeY5kfGmxbjDhd5NigQ>?			NGHxXVNC[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKGmwIFj1bFch[2WubIOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMkKg{txO	M{\mVFE4ODN2MUS5
HepG2 cells	NYLmdIU2TnWwY4Tpc44h[XO\|YYm=			NGn5PWhC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVJiZ3HtcYEhcW5iYTDI[ZBIOiClZXzsd{BjgSCSUFHSMWdCVDRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNVU5KM7:TR?=	NX3CfG1VOTZ7N{OzOVg>
HepG2 cells	Ml7QSpVv[3Srb36gZZN{[Xl?			NH7BcJNC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVJiZ3HtcYEhcW5iSHXwS\|Ih[2WubIOgZpkhWFCDUj3HRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkG1PO69VQ>?	MWqxOlk4QTN2MR?=
CV1 cells	M2T6eGZ2dmO2aX;uJIF{e2G7			NVSxUmgySWO2aY\peJkh[XRiaIXtZY4hWFCDUnfhcY1iKGmwIFPWNUBk\WyuczygSWM2OD1yLkOwPEDPxE1?	NIP0W48yPzByNUO5OC=>
HEK293 cells	NUjqfmlTTnWwY4Tpc44h[XO\|YYm=			M{\NWmFkfGm4aYT5JIF1KGi3bXHuJIFlcXCxc3WgeIl{e3WnIGDQRXIh\2GvbXGg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDifUBRWEGULVfBUFQhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwM{Gg{txO	MmDvNVc{PDN\|N{G=
rat L6 cells	M{nCeWZ2dmO2aX;uJIF{e2G7			MVPF[oZm[3Rib36g[oF1fHliYXPp[EBwgGmmYYTpc44hcW5icnH0JGw3KGOnbHzzMEBGSzVyPUWg{txO	M4TNSFE4OzR\|M{ex
HepG2 cells	Mn:xSpVv[3Srb36gZZN{[Xl?			M325U2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIlvKEincFeyJINmdGy\|IHL5JHBRSVJvR1HMOEB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yOEKg{txO	M37UeFE4OTV5MEG5
CV1 cells	MlqwSpVv[3Srb36gZZN{[Xl?			MmDtRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT[WyyaHGgbY4hS1ZzIHPlcIx{KGK7IFfBUFQhfHKjboPhZ5RqfmG2aX;uJIF{e2G7IHHmeIVzKDJ2IHjyd{whTUN3ME2zMlQ3KM7:TR?=	MYGxO\|UxPzJ{NR?=
CV1 cells	NYe3VpdlTnWwY4Tpc44h[XO\|YYm=			NUHDRpNkSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy\|IHL5JGdCVDRidILhcpNi[3SrdnH0bY9vKGG\|c3H5JIFnfGW{IEK0JIhzeyxiRVO1NF0xNjB\|IN88US=>	NVixNnEyOTd3MEeyNlU>
CV1 cells	NUToflNpTnWwY4Tpc44h[XO\|YYm=			MUnB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hS1ZzIHPlcIx{KGK7IILlZ4VxfG:{IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlMxQCEQvF2=	Mn;ENVgxOjlzN{i=
CV1 cells	M3zpW2Z2dmO2aX;uJIF{e2G7			NIi4NVVC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDDWlEh[2WubIOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwM{C4JO69VQ>?	MUixO\|EzQTd{NR?=
HEK293 cells	MUDGeY5kfGmxbjDhd5NigQ>?			MlrTRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BjgSCJQVy0JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB\|NTFOwG0>	NHf0XlIyPzJ7Mk[wOi=>
NIH3T3 cells	MWfGeY5kfGmxbjDhd5NigQ>?			MXTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hVkmKM2SzJINmdGy\|IHL5JGdCVDRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuN\|Ih\|ryP	M1T1TFE4PjJ2N{e3
HEK293 cells	NWPTblZ3TnWwY4Tpc44h[XO\|YYm=			MlXSRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BjgSCJQVy0JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjF7IN88US=>	NXXIZnJiOThyMkmxO\|Y>
HEK293 cells	MmLXSpVv[3Srb36gZZN{[Xl?			M{nRN2Fod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO\|ZYPz[YQh[XNiYWCyJIdmdmViaX7keYN1cW:wLDDFR\|UxRTBwMUKg{txO	NETwVVMyQDB{OUG3Oi=>
HEK293 cells	MXvGeY5kfGmxbjDhd5NigQ>?			NELRRYhC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDISWszQTNiY3XscJMh[nliR1HMOEB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yNEWg{txO	M332ZVE5OjlzNkS1
HepG2 cells	MmjwSpVv[3Srb36gZZN{[Xl?			NFfNT4lC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuNDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yM{mg{txO	NW\rOIN{OTh6M{W3NVk>
RAW264.7 cells	MVXGeY5kfGmxbjDhd5NigQ>?			NG\5SmFUfXCycnXzd4lwdiCxZjDMVHMwUU[QLXfhcY1iNXO2aX31cIF1\WRiTl:gdJJw\HWldHnvckBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczygSWM2OD1zNz61JO69VQ>?	MV:xPFgxQTN{NR?=
BL21 cells	M{L1NmZ2dmO2aX;uJIF{e2G7			M2[3b2Rqe3CuYXPlcYVvfCCxZjDyZYRqdyCuYXLlcIVlKDJqUzmtLFIu[mWwen;5cE1xcGWweXzhcYlvdylvMz37OE1cOSxzLXTpeJJqfGmxLUKtLFUudWW2aInsMVIueGinbonsMY95[XqxbD20MZltMS2ndHjvfJleNXCqZX75cJ0ueHKxcHnvcolkKGGlaXSg[pJwdSCJU2St[pV{\WRiaIXtZY4hWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZpkhe2OrboTpcIxifGmxbjDwdo95cW2rdImgZZN{[XluIFXDOVA:OC52NTFOwG0>	NYXBWWh4OTl\|NEmxO\|Y>
BHK21 cells	M2DpSWZ2dmO2aX;uJIF{e2G7			MULB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hSkiNMkGgZ4VtdHNiYYPz[ZN{\WRiYYOgV2VCWCCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjR3IN88US=>	MWGxPVM1QTF5Nh?=
HepG2/C3A cells	NHK5eG9HfW6ldHnvckBie3OjeR?=			MU\BZ5RqfmG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5vbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGmwIHj1cYFvKEincFeyM2M{SSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKG[3c3XkJGdidDRvTFLEJIJ6KGOxdILhcpNn\WO2aX;uJIF{e2G7LDDFR\|UxRTBwMECzPEDPxE1?	NHG1XIwyPzRyM{[4PC=>
HepG2 cells	NIm5SZlHfW6ldHnvckBie3OjeR?=			MkDJRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iC{ZXPldJRweiC2cnHud4FkfGm4YYTpc44h[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBGSzVyPUCuNFUh\|ryP	M4D0UFE5PjJ3NUW5
COS1 cells	MlLaSpVv[3Srb36gZZN{[Xl?			M3\kfGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gdoVkd22kaX7hcpQhWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDDU3MyKGOnbHzzJINwNWW6cILld5NqdmdiR1HMOEBie3Onc4Pl[EBieyC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjB{IN88US=>	M{ntfVE6PTB5OE[x
HepG2 cells	NWnYWFFUTnWwY4Tpc44h[XO\|YYm=			NIns[4NC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSHXwS\|Ih[2WubIOgZpkhT0GONDD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4zOjNizszN	MmjINVg{QTR7MEe=
CV1 cells	NE\KNWZHfW6ldHnvckBie3OjeR?=			M1fGNWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS1ZzIHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiZoXz[YQhT2GuND3ERmQh[nlidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNFM{KM7:TR?=	NVnySYpGOTh6Mk[yNFU>
CV1 cells	M{LrZmZ2dmO2aX;uJIF{e2G7			MVHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJidHCqYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKG[3c3XkJGdidDRvRFLEJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1\|LkS2JO69VQ>?	NX7FfVA3OTh6Mk[yNFU>
U2OS cells	M2DOT2Z2dmO2aX;uJIF{e2G7			MoHiRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgbY4hXTKRUzDj[YxteyCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4xOiEQvF2=	MVyxPFMzQTd3MR?=
Hep G2 cells	MXHGeY5kfGmxbjDhd5NigQ>?			MkfrRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDoeY1idiCKZYCgS\|Ih[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2LVTCSEBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wOEDPxE1?	NXq2UoM3OTlyNUO3O\|Y>
HeLa cells	NVzodotKTnWwY4Tpc44h[XO\|YYm=			NVPuV5NiSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOE1FSkRiYYPz[ZN{\WRiYYOgeJJidnOlcnnweIlwdmGuIHHjeIl3[XSrb36gZpkhT2GuNDDy[ZNxd26\|ZTDlcIVu\W62LXTybZZmdiCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wNVUh\|ryP	NFO5UZUyQTJ5NUm2Ny=>
COS1 cells	MnToSpVv[3Srb36gZZN{[Xl?			M1vhbWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3MyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIgh\nW\|ZXSgfYVie3RiR3HsOE1FSkRiYomgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODJizszN	NVzTTXU5OTl3M{C2PFE>
U2OS cells	MnuxSpVv[3Srb36gZZN{[Xl?			NUS2dXdMSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIGWyU3Mh[2WubIOgZpkhdHWlaX\ldoF{\SC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6wOUDPxE1?	NF7PT40yQTV5NEC1Oi=>
HepG2 cells	MlywSpVv[3Srb36gZZN{[Xl?			NYO4Wm1FSWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MZRi\2enZDDoeY1idiCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YNmeHSxcjD0doFve2GldHn2ZZRqd25iYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODN7IN88US=>	M{XCblE6Pzd3MU[5
HepG2 cells	MYfGeY5kfGmxbjDhd5NigQ>?			MUDB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUGWyR{KgZ4VtdHNiYomgS2FNPCC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6yNlMh\|ryP	MkDONVk4QDN2NES=
COS7 cells	NGrkUJZHfW6ldHnvckBie3OjeR?=			MVfB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JHBRSVKpYX3tZVIhVEKGIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy\|IHPv[ZhxemW\|c3nu[{BISUx2IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4yKM7:TR?=	MXSyNFE{QDd4Mh?=
COS7 cells	NF21UnpHfW6ldHnvckBie3OjeR?=			M1TYZmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gdoVkd22kaX7hcpQhWFCDUnfhcY1iOSCOQlSg[ZhxemW\|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV\|ch[2WubIOgZ49mgHC{ZYPzbY5oKEeDTESgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB\|IN88US=>	NV;lZXM2OjBzM{i3OlI>
HEK cells	NIPhc\|NHfW6ldHnvckBie3OjeR?=			NYq1XHZbSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LYTh[4dm\CCSUFHSZYxxcGFiY3jpcYVzcWNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUyClZXzsd{BjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MUCuOVgh\|ryP	Mo[4NlAzQTl{MUS=
HEK cells	MUDGeY5kfGmxbjDhd5NigQ>?			M{S3dmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gS2FNPC22YXfn[YQhWFCDUnfhcY1iKGOqaX3ldolkKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWsh[2WubIOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMEO1JO69VQ>?	NE[3RWczODJ7OUKxOC=>
3T3L1 cells	MXTGeY5kfGmxbjDhd5NigQ>?		MXq3JIRigXN?	NVfUOXVpUW6mdXP0bY9vKG:oIHHkbZBw\2WwZYPpd{BqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBtcXCrZDDhZ4N2dXWuYYTpc44h[W[2ZYKgO{Bl[Xm\|IHL5JG9qdCC{ZXSgU{B{fGGrbnnu[y=>	NGfEbXUzODV{N{m2PS=>
CHO-K1 cells	M1XQ[mZ2dmO2aX;uJIF{e2G7			NU\4fFB{WGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGNJVy2NMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfBUFQh[XO\|ZYPz[YQh[XNibIXjbYZmemG\|ZTDhZ5Rqfmm2eTDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5zIN88US=>	M4PScFIxPTJ5OU[5
HEK293T cells	MXnGeY5kfGmxbjDhd5NigQ>?	NU\FcVRIOSEQvF2=	NH3lUYMzPCCqcoO=	NGLyU25R[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hMWxDTCCneIDy[ZN{\WRiaX6gTGVMOjl\|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhfHKjboPhZ5RqfmG2aX;uJIF1KDFidV2gZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	NX3zeGZ5OjFyM{CyOlM>
CV1 cells	M3vLfmZ2dmO2aX;uJIF{e2G7			M1fubHRz[W6\|YXP0bZZifGmxbjDv[kBI[Wx2LX\1d4VlKGi3bXHuJHBRSVKpYX3tZUBFVkFiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6xJO69VQ>?	NUS1WI84OjFzMUK3PFQ>
HEK293 cells	NVTOclkzTnWwY4Tpc44h[XO\|YYm=		Mm\ZNVYhfG9iMkCgbJJ{	NXLYelRMXHKjboPhZ5RqfmG2aX;uJI9nKEejbESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNVYhfG9iMkCgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA1OyEQvF2=	NG[0OGkzOTF{OE[wNC=>
HepG2 cells	Mn;RSpVv[3Srb36gZZN{[Xl?	NHHZeIUyOCC3bX;sM2w>	NFznSZozPCCqcoO=	MmrFTY5kemWjc3WgbY4h\2y3Y3;z[UBkd26\|dX3weIlwdiCrbjDoeY1idiCKZYDHNkBk\WyuczDheEAyOCC3bX;sM2wh[W[2ZYKgNlQhcHK\|IILlcIF1cX[nIITvJINwdnS{b3y=	M{TKVVIyOjV4N{S4
3T3L1 cell	MoXlSpVv[3Srb36gZZN{[Xl?	MU[xJJVO		M3TUdmlv\HWldHnvckBw\iCvb4Xz[UA{XDOOMTDj[YxtKGSrZn\ldoVvfGmjdHnvckBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44hd2ZiaX70doFk\WyudXzhdkBtcXCrZDDkdo9xdGW2IHH0JFEhfU1iYomgU4ltKHKnZDDPJJN1[WmwaX7n	NFn5e5MzOTRyMUGxPC=>
CV1 cells	NEXONYVHfW6ldHnvckBie3OjeR?=		M1PxbFQxKGh?	M1fNOmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hMWxDTCCneIDy[ZN{\WRiaX6gR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuNDDh[pRmeiB2MDDodpMh[nlibIXjbYZmemG\|ZTDiZZNm\CC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6xJO69VQ>?	NYXUTotuOjF3MUWwOlM>
HepG2 cells	MlK1SpVv[3Srb36gZZN{[Xl?			NF:3O2JC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SC{ZXPldJRweiCneIDy[ZN{\WRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZpkhWFCURT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOSEQvF2=	NGL1VGUzOTR6MkS0Oi=>
HepG2 cells	MnS1SpVv[3Srb36gZZN{[Xl?			NFHGT4hVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIGDQVmU{NVSNLVz1Z{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wOUDPxE1?	M3ryXFIyPDVyNE[4
COS7 cells	M2jmNmZ2dmO2aX;uJIF{e2G7			NV21RYp2VW:mdXzheIlwdiCxZjDoeY1idiCSUFHS[4FudWFvTFLEJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuNDDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIITyZY5{[WO2aY\heIlwdiCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJIF{e2G7LDDFR\|UxRTBwMESzJO69VQ>?	MUSyNVg4OzB5MB?=
COS-1 cells	NIHYR29HfW6ldHnvckBie3OjeR?=		NHTXNYQzPCCqcoO=	MVTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmVvYnHz[YQhdHWvaX7vcYV1emmlIHHuZYx6e2m\|LDDFR\|UxRTBwMES4JO69VQ>?	MnzoNlIxPTFyNUS=
COS1 cells	MWHGeY5kfGmxbjDhd5NigQ>?		MXKyOEBpenN?	MkXZWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIH\1cIwhdGWwZ4ToJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iQ1;TNUBk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJHJZWmGucHjhJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4yOiEQvF2=	M4XTflIzOTl5M{m2
MG-63 cells	NHjuSo1HfW6ldHnvckBie3OjeR?=			NWfiWVRxSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIF3HMVY{KGOnbHzzJIJ6KHKncH;yeIVzKGenbnWtZoF{\WRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNFEyKM7:TR?=	M3n4NlIzOjJ3NkSx
COS1 cells	M3rCcWZ2dmO2aX;uJIF{e2G7			M1:1Z2JqdmSrbnegZYZncW6rdImgeI8hcHWvYX6ge4lt\CC2eYDlJHBRSVKpYX3tZUBNSkRiZYjwdoV{e2WmIHnuJGNQWzFiY3XscJMh[29vZYjwdoV{e2mwZzDHRWw1KGK7IIPjbY51cWyuYYTpc44heHKxeHntbZR6KGG\|c3H5	MYGyNlA4ODZyNB?=
MG-63 cells	NVTvOpp4TnWwY4Tpc44h[XO\|YYm=		M2[3cFI1KGi{cx?=	M3PKRm1w\HWuYYTpc44hd2ZiZoXscE1t\W6pdHigbJVu[W5icGPHOU1nfXOnZDDQVGFT\2GvbXGg[ZhxemW\|c3XkJIlvKE2JLU[zJINmdGy\|IHPvMYV5eHKnc4PpcocheEeYLWCyMXBRWkViYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBj[XOnZDD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4xOTFizszN	Mli2NlI4Ojd2NEi=
Ac2F cells	NFPIVZBHfW6ldHnvckBie3OjeR?=	NHXwZ\|kxNjFidH:gNVAh\|ryP	MXm2JIhzew>?	MofFRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5icnH0JGFkOkZiY3XscJMh[XO\|ZYPz[YQh[XNibIXjbYZmemG\|ZTDhZ5Rqfmm2eTDheEAxNjFidH:gNVAhfU1iYX\0[ZIhPiCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	NYfWRWFrOjJ6MUmxPVA>
293H DA cells	M1faVmZ2dmO2aX;uJIF{e2G7		M4LudFE3KGh?	MWTB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBNSkRiaX6gbJVu[W5iMkmzTEBFSSClZXzsd{Bi\nSncjCxOkBpenNiYomgWHIuTlKHVDDhZ5RqfmG2aX;uJJJmeG:{dHXyJIF{e2G7LDDFR\|UxRTBwMECyOEDPxE1?	Mny3NlI2QDJ7N{O=
3T3L1 cells	M3e2TGZ2dmO2aX;uJIF{e2G7	M1LKXVExKHWP		MVnJcoNz\WG\|ZTDpckBi\Gmyb37lZ5RqdiCvUl7BJIxmfmWuczDpckBVVk[jbIDoZU1qdmS3Y3XkJI1wfXOnIEPUN2wyKGOnbHzzJJBz\XS{ZXH0[YQh[XRiMUCgeW0h[mWob4LlJHRPTi2jbIDoZUBkcGGubHXu[4UhemWuYYTpeoUhfG9iY3;ueJJwdA>?	M{PiUlIyQDVzMEi5
HepG2 cells	MW\GeY5kfGmxbjDhd5NigQ>?	NULEWVc{OTBidV2=	MUeyOEBp	NU[1bnNQWmWmdXP0bY9vKG:oIHfseYNwe2ViY3;ud5VueHSrb36gbY4hcW6\|dXzpck1z\XOrc4ThcpQhcHWvYX6gTIVxTzJiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JIdtfWOxc3Wgc5hq\GG\|ZTDt[ZRpd2RiaX6gdJJme2WwY3Wgc4YhOjJwMjDtUUBw\iCpbIXjc5Nm	NWPBUZBMOjNyMkWyOFQ>
HepG2 cells	NUXSOXFjTnWwY4Tpc44h[XO\|YYm=	MUOxNEB2VQ>?	M33y[\|I1KGh?	NIXUOXNT\WS3Y4Tpc44hd2ZiZ3z1Z49{\SClb37zeY1xfGmxbjDpckBqdnO3bHnuMZJme2m\|dHHueEBpfW2jbjDI[ZBIOiClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomg[4x2[2:\|ZTDvfIll[XOnIH3leIhw\CCrbjDwdoV{\W6lZTDv[kAxNjFidV2gc4YhcW6\|dXzpci=>	NEfLeVQzOzB{NUK0OC=>
THP1 cells	MlXMSpVv[3Srb36gZZN{[Xl?	Mk\rNVAxKHWP	MmHQN{BpenN?	MorTWJJidnOjY4TpeoF1cW:wIH;mJHBRSVKpYX3tZUBqdiCqdX3hckBVUFBzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGxRWy2rbnT1Z4VlKE2FUEGgcXJPSSCneIDy[ZN{cW:wIHH0JFExOCC3TTDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KHC{aX;yJJRwKEySUzDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	NHKzZ5UzOjl\|NEWzOy=>
THP1 cells	NILZZmxHfW6ldHnvckBie3OjeR?=	NGnkS3gyODBidV2=	NGGzd3Y{KGi{cx?=	M1\aZ3Rz[W6\|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhcW5iaIXtZY4hXEiSMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBNWFNvaX7keYNm\CCLTE[gcXJPSSCneIDy[ZN{cW:wIHH0JFExOCC3TTDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KHC{aX;yJJRwKEySUzDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	NILD[\|YzOjl\|NEWzOy=>
HepG2 cells	M2LP[WZ2dmO2aX;uJIF{e2G7			NELuSXFVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJJRz[W6\|ZnXjeIVlKGmwIHj1cYFvKEincFeyJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjFizszN	NULXVpV1OjJ7M{S1N\|c>
HepG2 cells	M4ntS2Z2dmO2aX;uJIF{e2G7		MoG0NlAhcA>?	NXT2bZhwSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LX\1d4VlKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW\|c3XkJIlvKEincFeyJINmdGy\|IHHmeIVzKDJyIHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMEKg{txO	MV[yNlA5OTl\|Mh?=
BL21 DE3 cells	MV3GeY5kfGmxbjDhd5NigQ>?			NVP5NnhUTGm\|cHzhZ4Vu\W62IH;mJHs{UF2{b4Pp[4xqfGG8b37lJIZzd21iTj30[ZJucW6jbDDIbZMufGGpZ3XkJIh2dWGwIGDQRXJo[W2vYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBFTTNiY3XscJMh[nlic3PpcpRqdGyjdHnvckBxem:6aX3peJkh[XO\|YYmsJGtqRTBwMEe0JO69VQ>?	MVyyNlA5OTl\|Mh?=
human L02 cells	MmO3SpVv[3Srb36gZZN{[Xl?			NFzPZ3ZC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[S2OQlSg[ZhxemW\|c3XkJIlvKGi3bXHuJGwxOiClZXzsd{Bkdy2neIDy[ZN{cW6pIIDHUFMuW1Z2MD3HRWw1KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZoF{\WRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuPUDPxE1?	NIniVlQzOzF6NkOwOy=>
HepG2 cells	MkTZSpVv[3Srb36gZZN{[Xl?		NIDsbokzOCCq	NGn5RpZVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBJ\XCJMjDj[YxteyCjZoTldkAzOCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxRTBwMEO5JO69VQ>?	NFTYdIkzOzF5MUC0OS=>
HEK293 cells	NVroelRvTnWwY4Tpc44h[XO\|YYm=	NXW0OlJPOTBizszN		MmfMWJJidnOjY4TpeoF1cW:wIH;mJHBRSVKpYX3tZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBCWDJvUGDSSUBifCBzMDD1UUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	MWWyN\|I4OzVzOR?=
HEK293 cells	MlLzSpVv[3Srb36gZZN{[Xl?			M1HXTWFod26rc4SgZZQhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gbJVu[W5iSFXLNlk{KGOnbHzzJINwfHKjboPm[YN1\WRid3n0bEBISUx2LVz1Z{Bie3Onc4Pl[EBieyC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xODRizszN	NHzwZXAzOzJ6Nke4Oy=>
HEK293 cells	NX7IfXJQTnWwY4Tpc44h[XO\|YYm=		NH:zOowzPCCq	M3XuVHRz[W6\|YXP0bZZifGmxbjDv[kBISUx2IFTCSE1nfXOnZDDoeY1idiCSUFHS[4FudWFvTFLEJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlEh\|ryP	MYqyN\|I6PDh\|MB?=
HEK293 cells	MoXGSpVv[3Srb36gZZN{[Xl?		NYLicmVqPDhiaILz	NV;TcZV{SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bkd3S{YX7z[oVkfGWmIIfpeIghWFCURYi0MXRMNWy3YzDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIHz1Z4ln\XKjc3WgZYN1cX[rdImgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME20N{44OSEQvF2=	M2X1fVI{OjZ3OES0
HepG2 cells	M1rSdWZ2dmO2aX;uJIF{e2G7			NIfNSW9C\2:waYP0JIFkfGm4aYT5JIF1KEeDTESt[pV{\WRiUGDBVodidW2jIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkCxJO69VQ>?	M2DRblI{PTB{MkGy
HepG2 cells	NHLPWI5HfW6ldHnvckBie3OjeR?=			Mo\aRYdwdmm\|dDDhZ5Rqfmm2eTDheEBISUx2LX\1d4VlKFCSQWLnZY1u[SCPNE[zRUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[nlidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNFAzKM7:TR?=	NInV[YMzOzVyMkKxNi=>
L6 cells	MYjGeY5kfGmxbjDhd5NigQ>?		M3TBUlI1KGi{cx?=	MWrJcoR2[3Srb36gc4Yh\2y3Y3;z[UB2eHSja3WgbY4hemG2IFy2JINmdGy\|IID1cJNm\CC5aYToJGMyPC2mZX;4fUBodHWlb4PlJIFnfGW{IEK0JIhzeyCrbjDwdoV{\W6lZTDv[kBqdnO3bHnuMEBGSzVyPUSuOFkh\|ryP	NFnSfZozOzl7Mki2Ni=>
L6 cells	NVThVGxMTnWwY4Tpc44h[XO\|YYm=		NVzR[nF7OTZiaILz	NEm4doxKdmO{ZXHz[UBqdiB{LWuzTH0u\GWxeInncJVkd3OnIIXweIFs\SCrbjDyZZQhVDZiY3XscJMh[W[2ZYKgNVYhcHK\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXNuIFXDOVA:PC56IN88US=>	MUGyOFgyOzd\|OB?=
DU145 cells	MlvXR5l1d3SxeHnjbZR6KGG\|c3H5		MortOFghcHK\|	NEexe2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDFR\|UxRTF4IN88US=>	MkL1NlQ6QTZzNEO=
PC3 cells	NWmyOZhbS3m2b4TvfIlkcXS7IHHzd4F6		MV20PEBpenN?	MmPvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEWFNUC9NlAvOyEQvF2=	NUjqfFUxOjR7OU[xOFM>
MDA-MB-231 cells	M2Lxbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGHCRm8zPCCqcoO=	NVXMcIZXT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBGSzVyPUWuNlMh\|ryP	NULF[o1bOjV{N{iyN\|Y>
HEK293 cells	NF\GZppHfW6ldHnvckBie3OjeR?=			MUfB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzIN88US=>	NHXa[oEzPTNyNU[4PC=>
HepG2 cells	M36xO2Z2dmO2aX;uJIF{e2G7		MYKyNEBpenN?	NW\yVZBkXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWKgeJJidnOoZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhOjBiaILzJIJ6KFCSQWKtcJVkcW[ncnHz[UBie3OjeTygSWM2OD1zLk[g{txO	M{X6cFI2PDN5M{C0
HEK293 cells	MmnKSpVv[3Srb36gZZN{[Xl?		Ml;KNlQhcHK\|	NV2wNpNmXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWLnZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	Mn\SNlU1PDJ\|MkK=
HepG2 cells	NFv4Vm1HfW6ldHnvckBie3OjeR?=			NUL5dXdKSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LWDQRXJo[W2vYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHj1cYFvKEincFeyJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjB\|OTFOwG0>	NV3kUVlxOjV2NkKyPFE>
HEK293 cells	NFXZU\|BHfW6ldHnvckBie3OjeR?=		M2\UNFI1KGi{cx?=	MYXB[49vcXO2IHHjeIl3cXS7IHH0JI1wfXOnIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHPvMYV5eHKnc4Ppcochf2m2aDDHZYw1KHKncH;yeIVzKH[nY4TvdkBi\nSncjCyOEBpenNiYomg[JVidC2udXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCHQ{WwQVAvODNizszN	NGThXpgzPDl3NUi4PS=>
HepG2 cells	NWroXm4yTnWwY4Tpc44h[XO\|YYm=		M17Re\|IxKGi{cx?=	NIHqNpdC\2:waYP0JIFkfGm4aYT5JIF1KEeDTEStSG5CKGKrbnTpcoch\G:vYXnuJIZ2e2WmIHj1cYFvKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW\|c3XkJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILlZ4VxfG:{IITyZY5{[WO2aY\heIlwdiCrbnP1ZoF1\WRiZn;yJFIxKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yNDFOwG0>	MWiyOVQ6PzF\|Mh?=
HepaR cells	NETpO\|ZHfW6ldHnvckBie3OjeR?=		NGnyS4wyKGSjeR?=	MYDB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCqdX3hckBJ\XCjUjDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBJVUeFU{Kg[4Vv\SCneIDy[ZN{cW:wIHH0JFEhfU1iaX7jeYJifGWmIH\vdkAyKGSjeTDifUByfWGwdHn0ZZRqfmViUFPSJI1mfGixZDDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=>	MY[yOVQ6PzF\|Mh?=
HepaR cells	MWPGeY5kfGmxbjDhd5NigQ>?	NH;sSpQyKHWP	M1\ubFEh\GG7	MonSRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyYWKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hSU6JUGTMOEBo\W6nIHX4dJJme3Orb36gZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDFiZHH5JIJ6KHG3YX70bZRifGm4ZTDQR3IhdWW2aH;kJJJmdGG2aY\lJJRwKHWwdILlZZRm\CClb370do9t	MoP2NlU1QTdzM{K=
HepaR cells	Ml;VSpVv[3Srb36gZZN{[Xl?	M1jRNlEhfU1?	NILFUJcyKGSjeR?=	MmPTRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyYWKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hTkGEUEGg[4Vv\SCneIDy[ZN{cW:wIHH0JFEhfU1iaX7jeYJifGWmIH\vdkAyKGSjeTDifUByfWGwdHn0ZZRqfmViUFPSJI1mfGixZDDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=>	MUiyOVQ6PzF\|Mh?=
HEK293 cells	MnSzSpVv[3Srb36gZZN{[Xl?	M3HDZ\|ExKM7:TR?=	NHfJRXQzPCCqcoO=	NI\zeI1VemGwc3HjeIl3[XSrb36gc4YhWFCDUj3nZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	MYGyOFg6ODB7MB?=
C2C12 cells	M1XiRmZ2dmO2aX;uJIF{e2G7	MUCzNEDPxE1?	M2Luc\|IhcA>?	MmDQTY5lfWO2aX;uJI9nKDJvZHXvfJkuYzOKXT3ncJVkd3OnIIXweIFs\SCrbjDtc5V{\SCFMlOxNkBk\WyuczDheEA{OCC3TTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDhcoFtgXOrcx?=	Mlf1NlU5OzV3M{e=
MCF7 cells	Mme2SpVv[3Srb36gZZN{[Xl?		M2Xnd\|E3KGh?	M1XTbmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJJRz[W6\|ZnXjeIVlKGmwIHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOTZiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkC4O{DPxE1?	Ml\sNlYzOjZ2OUC=
HEK293 cells	MWrGeY5kfGmxbjDhd5NigQ>?	NGTG[JAyOCEQvF2=	NITUPHQzPCCq	NXnNeZpDSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILlZ4VxfG:{IITyZY5{[WO2aY\heIlwdiCjdDCxNEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	M4C0clI3Ozh2Mki2

... Click to View More Cell Line Experimental Data

Protocol

References

Solubility (25°C)

In vitro	DMSO	35 mg/mL (198.67 mM)
	Ethanol	35 mg/mL (198.67 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Methylumbelliferone (4-MU) SDF

Molecular Weight	176.17
Formula	C₁₀H₈O₃
CAS No.	90-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=O)OC2=C1C=CC(=C2)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Related Others Products

Telaglenastat (CB-839) ^New

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Setanaxib (GKT137831) ^New

Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis.
LB-100 ^New

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Puromycin (CL13900) 2HCl

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A (NSC 290193)

Cyclosporin A (Cyclosporine A, Cyclosporine, Ciclosporin, CsA) is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Cyclophosphamide (NSC-26271) Monohydrate

Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Ganciclovir (BW 759)

Ganciclovir (RS-21592, BW-759, 2'-Nor-2'-deoxyguanosine) is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Calcitriol (RO215535)

Calcitriol (RO215535, Topitriol, 1,25-Dihydroxyvitamin D3) is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol. Solutions are best fresh-prepared.
Ribavirin (ICN-1229)

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
N6-methyladenosine (m6A)

N6-methyladenosine (m6A, NSC-29409, 6-Methyladenosine, N-Methyladenosine) is a base modified analog of adenosine and is found as a minor nucleoside in natural RNAs.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Methylumbelliferone (4-MU)